At the Leipzig Interventional Course (LINC 2015), Stephan Duda presented findings from the ILLUMENATE FIH (first-in-human) study that demonstrate primary patency at 12 months of 89.5% in the pre-dilation plus drug-coated balloon group and 77.5% in the direct balloon group, when using the Stellarex drug-coated balloon.
Data presented at the Leipzig Interventional Course 2015 (LINC, 27– 30 January, Leipzig, Germany) demonstrate significant improvement in dissection repair with the Tack Endovascular System (Intact Vascular).
Transcatheter Technologies is further expanding its product platform to include an endoVascular aortic repair (EVAR) device: Tumbao
A European multicentre analysis of 123 patients treated for mycotic aortic aneurysms with endovascular repair demonstrates this approach is feasible, with 91% survival at 30 days, and for most patients a durable option. The authors, however, also show that a significant number (19%) of fatal infection-related complications occur.
In November 2014, Jotec received CE mark approval for the new E-tegra AAA Stent Graft System. The stent graft system is indicated for endovascular treatment of infrarenal abdominal aortic aneurysms and, according to the company, incorporates numerous innovative technical solutions with respect to implant and delivery system.
The early results obtained using this new minimally invasive technique that uses both coil embolization and foam as a sclerosing agent were published in the journal Phlebology in December 2014. The study shows that the technique, which associates a mechanical interruption of the sapheno-femoral junction to classic sclerotherapy with no need for surgery or anaesthesia, is effective, nearly painless and appears cost-effective in a small group of patients with short follow-up.
According to a study presented at the 2014 European Society for Vascular Surgery (ESVS) meeting (23–25 September, Stockholm, Sweden), a standardised perioperative protocol for immediately diagnosing spinal cord ischaemia after thoracic endovascular aortic aneurysm repair (TEVAR) for the management of thoracoabdominal aortic aneurysms may lead to improved recovery after the complication.
Preliminary results from the INNOVATION study indicate that Cordis’s Incraft stent graft is not associated with any type Ia or type III endoleaks at three years for patients undergoing endovascular aortic aneurysm repair (EVAR). They also show that the device is associated with a freedom from sac increase rate of 95.6%.
The results of a landmark study published in Circulation indicate that Medtronic’s In.pact Admiral drug-coated balloon (DCB) significantly outperformed standard balloon angioplasty in the treatment of symptomatic peripheral artery disease in the upper leg, specifically, the superficial femoral and proximal popliteal arteries.
biolas has announced the launch of its VariClose vein sealing systems in Europe.
In the United States ruptured abdominal aortic aneurysms account for 15,000 to 30,000 deaths per year. Open surgical repair had been the “gold standard” but was associated with significant morbidity and mortality, and with the advent of elective aortic aneurysm repair with endovascular techniques, this technology was transferred to the treatment of ruptured aneurysms.
Ensuring that patients with peripheral arterial disease get tested and treated with minimally invasive endovascular therapy saves legs and lives, suggests a study in which amputation rates fell by nearly 80% after such a system was implemented.
Three-year follow-up results of patients treated with the Supera stent show that nominal deployment or slight compression of the device delivers the best outcomes in terms of durability, and that severe stent elongation provides the lowest durability through three years. With nominal deployment, the freedom from reintervention rate was 97% at one year and 94% at three years – a “minimal decrease”, according to Lawrence Garcia, who presented the results at the VEITHsymposium (18–22 November, New York, USA).
Lombard Medical has released efficacy and safety data from the two-year follow up of the US PYTHAGORAS pre-marketing approval (PMA) trial of Aorfix, the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees.
Studies presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in vulnerable populations, such as cancer patients.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos